39 results about "Retinal pigment epithelium cell" patented technology

Proliferation of retinal pigment epithelium following surgery or trauma or resulting in ocular diseases associated with choroidal neovascularization, such as age related macular degeneration and histoplasmosis syndrome, is prevented by contacting retinal pigment epithelium cells with a therapeutic amount of a retinoic acid receptor (RAR agonist, preferably one with specific activity for retinoic acid receptors. Preferably the RAR agonist is also a potent antagonist of AP1-dependent gene expression. Alternatively, the proliferation of retinal pigment epithelium is ameliorated with a therapeutic amount of an AP-1 antagonist, alone or in combination with an RAR agonist. The drug can be administered by bolus injection into the vitreous cavity using a dosage from about 50 to 150 .mu.g. Or by slow release from liposomes or an oil tamponade injected into the vitreous cavity. Formulations for preventing proliferation of retinal pigment epithelium are also provided.

The invention discloses a preparation and amplification culture method of human multipotential stem cell sourced human retinal pigment epithelium cells. The method comprises the following steps of collecting a 3D-RPE sphere from the human multipotential stem cell sources; performing mechanical separation, removing non-RPE cells or agglomerates containing no pigments; remaining RPE cell sheets containing the pigments; performing enzymolysis digestion on the pigment-containing RPE cell sheets to obtain RPE unicellular suspension; thus obtaining the human multipotential stem cell sourced human retinal pigment epithelium cells. The features of the human RPE cells prepared by the method are similar to the features of human embryo sourced RPE cells; the typical RPE cell form features are realized; the normal physiological functions are shown. The human RPE cells prepared by the method can realize the subculture; the mass amplification is realized; the seed cells are provided for the study and treatment of retinal diseases; benefits are brought to blind patients; the problem of important defects of limited retinal pigment epithelium cells and RPE transplanting donor lack in the prior artcan be solved; great significance is realized.

Disclosed is a complex for remedying or treating a retinal disease. The complex includes a hyaluronic acid or a derivative thereof, a carbon nanomaterial covalently bonded to the hyaluronic acid or the derivative thereof, and a photosensitizer bonded to the carbon nanomaterial. The complex for remedying or treating the retinal disease according to the present invention includes a hyaluronic acid-carbon nanomaterial-photosensitizer complex, thus selectively preventing the formation of active oxygen in retinal pigment epithelium cells for a relatively long period of time. Accordingly, the complex has excellent therapeutic efficacy and easily infiltrates into cells. Further, the present invention provides a composition for remedying or treating a retinal disease including the hyaluronic acid-carbon nanomaterial-photosensitizer complex.

Provided herein are methods of producing an RPE cell population from a starting cell suspension, such as a single cell suspension, of pluripotent stem cells (PSCs). Such a method may comprise culturing the starting single cell suspension of PSCs in differentiation media to produce human RPE cells.

The invention relates to a preparation method of a hydrogel cell support used for promoting multiplication of retinal pigment epithelium cells. Electrolyte macromolecule monomer solution and neutral macromolecule monomer solution are mixed to be uniform, an initiator is added, mixing to be uniform is carried out again, deoxidizing is carried out by utilizing nitrogen under the condition of dark place, and then mixture is added into a platy composite die. The prepared hydrogel cell support overcomes the defects that the traditional hydrogel cell support is easy to be aged and can not be effectively adhered on retina and transplanted retinal pigment epithelium cells can not be adhered on fovea to form a cell layer, adhesion, spreading and multiplication of the retinal pigment epithelium cells of human body can be realized and promoted, and a macromolecule hydrogel cell support with anti-ageing function can be realized.

Bioprosthetic retinal grafts (or devices) comprising stem cell derived tissues and/or cells may be used to slow the progression of retinal degenerative disease, slow the progression of retinal degenerative disease after traumatic injury, slow the progression of age related macular degeneration (AMD), prevent retinal degenerative disease, prevent retinal degenerative disease after traumatic injury,prevent AMD, restore retinal pigment epithelium (RPE), photoreceptor cells (PRCs) and retinal ganglion cells (RGCs) lost from disease, injury or genetic abnormalities, increasing RPE, PRCs and RCGs,treat RPE, PRCs and RCG defects in a subject, or for other purposes. Bioprosthetic retinal grafts may comprise a bioprosthetic carrier or scaffold suitable for implantation into the ocular space of asubject's eye, to form a bioprosthetic retinal patch. In certain embodiments, the bioprosthetic retinal patch may comprise multiple pieces of stem cell derived tissues or cells on a carrier or scaffold, which may be used to treat large areas of retinal degeneration or damage, or for other purposes.

The invention relates to a method for measuring retina morphology of an eyeball. The method comprises the following steps: (1) layering a retina image measured by OCT by adopting professional OCT image analysis software; (2) selecting an OCT image of a retinal pigment epithelium cell layer; (3) correcting the OCT image in the step (2), so that the OCT image coincides with a standard human eye model; and (4) calculating the morphological parameters of the retina according to the corrected OCT image. According to the method for measuring the retina morphology of the eyeball provided by the invention, the convenient OCT is used for measuring the retina morphology of the eyeball, the portable OCT can be carried outside a hospital, and the method can be widely applied to epidemiological investigation and research of large samples. The method can be widely popularized in population epidemiological research, the cost is reduced, the method is suitable for a wide range of people, and a necessary technical means is provided for relevant research.

This invention relates to novel method of treating or ameliorating a retinal disease or disorder or retinal degradation in a subject and a novel method of restoring retinal pigment epithelium cell compromising the administration of a one or more compounds which modulate Nox4, formation of radical oxygen species, serine protease, a dopamine receptor, NF-kB, mTOR, AMPK, RPE epithelial to mesenchymal transition, RPE dedifferentiation, or one or more Rho GTPases; and kits for administration of the methods.

The invention relates to the technical field of biology, and particularly discloses application of a small molecule compound composition in preparation of a medicine for preventing and treating retinal injury diseases. The small molecule compound composition effectively antagonizes cell death and dysfunction caused by oxidative stress on retinal pigment epithelial cells, and can effectively protect the retinal pigment epithelial cells so as to protect the structural integrity and normal function of the whole retinal layer cells; the compound can be used for preventing and potentially treating retinal injury caused by oxidative stress, and is particularly favorable for preventing and/or treating age-related maculopathy and other retinal injury diseases. Besides, experiments prove that the small molecule compound composition has no obvious pharmacological toxicity and can effectively control occurrence and development of retinal injury diseases, and a new theoretical support is provided for development of unknown biological activity and future clinical treatment effects of the small molecule compound composition.

The present invention provides an agent for treating ophthalmic diseases and a screening method for an agent for treating ophthalmic diseases and the like. The present invention also provides a method for predicting rejection associated with transplantation of retinal pigment epithelial cell to patients with ophthalmic diseases.

The invention relates to use of a kudzu flower extract in prevention and treatment on oxidative damage. Specifically, the invention provides use of the kudzu flower extract in preparation of compositions. The compositions are applied to one or more uses as follows: (i) prevention and/or treatment on the oxidative damage; (ii) prevention and/or treatment on oxidative-damage-related diseases; and (iii) uveitis. The kudzu flower extract disclosed by the invention can be used for remarkably inhibiting or reducing active oxygen radicals, thereby being applied to the prevention and/or treatment on the oxidative damage and related diseases thereof such as retinal pigment epithelium lesion and the uveitis.

The invention relates to the technical field of biology, in particular to a preparation method and application of recombinant VEGFB (vascular endothelial growth factor B). The preparation method of the recombinant VEGFB mainly comprises a purification method of the recombinant VEGFB and comprises the steps of inclusion body dissolution, affinity chromatography purification, renaturation and gel filtration chromatography, and the recombinant VEGFB obtained through purification not only has good yield and purity, but also has good physiological activity and has a good protection effect on retinal pigment epithelial cells.

The present invention provides a sustained drug delivery system for the treatment of age-related macular degeneration (AMD), comprising corticosteroid encapsulated nanoparticles incorporated into a thermoreversible hydrogel. The corticosteroid may be triamcinolone acetate (TA), dexamethasone, or loteprednol etabonate (LE). The proposed drug delivery system is nontoxic to ARPE-19 (retinal pigment epithelium) cells and significantly reduces VEGF (vascular endothelial growth factor) expression as compared to solutions of the coticosteroids. The present invention provides sustained delivery of the corticosteroid to the posterior segment of the eye, reducing the frequency of intraocular injections necessary to maintain therapeutic concentrations.

The invention provides application of combined use of RepSox and Y27632 in preparation of a medicine for reversing epithelial-mesenchymal transition (EMT) of retinal pigment epithelium (RPE). According to the application of combined use of RepSox and Y27632 in preparation of the medicine for reversing epithelial-mesenchymal transition (EMT) of retinal pigment epithelium (RPE) provided by the invention, the EMT of the RPE can be effectively reversed; the form of the retina is maintained; and the visual function is improved. The strategy is expected to provide a new treatment medicine combination and treatment scheme for clinically treating diseases caused by the EMT of the RPE, such as PVR and AMD.

The invention provides application of thrombospondin 1 (THBS-1) in preparation of a medicine for preventing and/or treating age-related macular degeneration (AMD), and belongs to the technical field of eye disease medicines. As the pathological process of the AMD comprises injury and death of retinal pigment epithelium (RPE), formation of choroidal neovascularization (CNV) and retinal inflammation, in-vitro cell experiments and in-vivo animal experiments are combined to verify the anti-inflammatory effect of the THBS-1 in experimental blue light induced retinal inflammation and verify the effect of the THBS-1 in inhibition of pathological neovascularization and the protection effect of retinal injury. Therefore, the invention provides the application of the THBS-1 in preparation of the medicine for preventing and/or treating the AMD.

The invention belongs to the field of pharmacy, disclosing a novel purpose of lipoamide which is used for preparing a preparation for preventing or curing diseases being relevant to cell trauma. The invention discloses the novel purpose at the aspect of preventing and curing cell trauma for the first time; in addition, the extremely effective easing and curing function of the lipoamide to the trauma of retinal pigment epithelium cell is disclosed for the first time, the pharmacological actions are very obvious, no any toxic and side effects appear and the admirable medicated prospect can be reached.